In the attempt to better define the molecular mechanisms leading to Nrf2 activation in thyroid cancer, several Nrf2-gain-of-function and Keap1-loss-of-function somatic mutations were described in many human cancers in different tissues, including the liver, kidneys, lungs, and others [43,45]. This evidence concerns the gene NFE2L2 and thyroid gland carcinoma.